Why the study?
What are the pharmacodynamic properties of tinzaparin given as a single daily administration in healthy volunteers?
What are the pharmacodynamic properties of tinzaparin given as a single daily administration in healthy volunteers?
Answers are grounded in this paper and cite their sources.
The antithrombotic and prohaemorrhagic effects of low molecular weight heparins appear independent of absolute antifactor Xa activity levels and APTT prolongation.
We report the pharmacodynamic properties of tinzaparin (175 U/kg antifactor Xa) given as a single daily administration for 5 consecutive days to 14 healthy volunteers as a known safe, effective treatment of deep vein thrombosis and pulmonary embolism. The Cmax for antifactor Xa (0.87 +/- 0.15 U/ml) was associated with a 2.4 +/- 0.5-fold prolongation of the activated partial thromboplastin time (APTT) and a high antithrombin activity (0.38 +/- 0.1 U/ml). The Cmax value of antifactor Xa was 1.5- and twofold lower than those generated by similar doses of nadroparin and enoxaparin respectively. The clearance of antifactor Xa activity (1.29 +/- 0.2 l/h) was 1.5- and twofold greater than those reported for nadroparin and enoxaparin respectively. These results indicated that the antithrombotic and prohaemorrhagic effects of a low molecular weight heparin were independent from the absolute levels of antifactor Xa activities and from the prolongation of the APTT.
No takes yet. Share an insight, caveat, or question.
Cambus et al. (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: